SCHEMBL6609943

SCHEMBL6609943

COC(=O)C(CO)N(Cc1ccc(Cl)cc1N)S(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.47
MMP7 P09237 1/20 0.47
MMP8 P22894 1/20 0.47
MMP12 P39900 1/20 0.47
MMP13 P45452 1/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
KEAP1 Q14145 3/20 0.45
NFE2L2 Q16236 1/20 0.45
BMP1 P13497 10/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655796 0.86 KEAP1 (0.56) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6608022 0.86 MMP1 (0.53) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6610164 0.84 BMP1 (0.48) MMP1MMP7MMP8MMP12MMP13
SCHEMBL7389789 0.83 KEAP1 (0.44) MMP1MMP7MMP8MMP12MMP13
SCHEMBL8023076 0.77 KEAP1 (0.46) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6608765 0.76 KEAP1 (0.64) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6608519 0.76 MMP1 (0.55) MMP1MMP7MMP8MMP12MMP13
SCHEMBL6613444 0.75 KEAP1 (0.53) MMP1MMP7MMP8MMP12MMP13
SCHEMBL5654237 0.75 MMP1 (0.69) MMP1MMP8MMP13KEAP1NFE2L2
SCHEMBL6616241 0.75 MMP1 (0.54) MMP1MMP7MMP8MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1147095-B1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH CORP (US) 2004-08-11 EP disclosed
US-6544984-B1 Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. AMERICAN CYANAMID COMPANY 2003-04-08 US disclosed
EP-1147095-A1 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2001-10-24 EP disclosed
EP-1051407-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS American Cyanamid Company (US) 2000-11-15 EP disclosed
WO-2000044730-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-08-03 WO disclosed
US-6071903-A ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-06-06 US disclosed
WO-1999037625-A1 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS AMERICAN CYANAMID COMPANY (US) 1999-07-29 WO disclosed